title: The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016.
abstract: After the introduction of systemic targeted therapies, the use of nephrectomy in patients with metastatic renal cell carcinoma has declined. Currently, systemic therapy is offered to more patients first as a means to select those candidates that will likely benefit from removal of their primary tumour. Although studies consistently demonstrate a survival benefit after nephrectomy, most patients with poor risk metastatic disease are unlikely to benefit from surgery. Soon studies will report on the effect of nephrectomy in patients with metastatic disease at diagnosis.
authors.affiliation: Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.bex@nki.nl.
authors.forename: Axel
authors.initials: A
authors.lastname: Bex
authors.affiliation: Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
authors.forename: Börje
authors.initials: B
authors.lastname: Ljungberg
authors.affiliation: Department of Urology, University Hospitals of the KULeuven. Leuven, Belgium.
authors.forename: Hein
authors.initials: H
authors.lastname: van Poppel
authors.affiliation: The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
authors.forename: Thomas
authors.initials: T
authors.lastname: Powles
mesh_terms: D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000601:surgery*; D065426:Cytoreduction Surgical Procedures; D005060:Europe; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery*; D009362:Neoplasm Metastasis; D009392:Nephrectomy; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D014572:Urology
keywords: Cytoreductive; EAU; Guidelines; Management; Metastatic; Nephrectomy; Performance score; Renal cell cancer